Table 2.

Non-hematologic adverse events of all CTCAE grades and grade 3–4

Non-hematologic adverse events	Number of subjects (N)	Number of studies (k)	I2	Fixed effect	95% CI	Random effect	95% CI
Adverse event (overall)
Fatigue	1,000	10	93.9	0.426	0.395–0.456	0.401	0.276–0.533
Nausea	715	7	82.1	0.357	0.323–0.393	0.339	0.252–0.432
Constipation	1,112	12	96.7	0.31	0.283–0.337	0.341	0.207–0.489
Alopecia	416	4	71.5	0.273	0.232–0.317	0.26	0.163–0.371
Infusion-site reaction	508	5	95.6	0.257	0.220–0.296	0.34	0.023–0.789
Vomiting	854	9	90.4	0.249	0.220–0.278	0.219	0.128–0.326
Mucositis	644	6	87.3	0.212	0.181–0.244	0.184	0.099–0.289
Abdominal pain	917	9	84.1	0.178	0.154–0.203	0.168	0.101–0.247
Myalgias	567	5	8.8	0.154	0.125–0.185	0.154	0.125–0.185
Neuropathy	805	7	92.5	0.151	0.127–0.177	0.157	0.071–0.271
Adverse event (grade 3–4)
Fatigue	1,381	14	91.3	0.113	0.097–0.131	0.102	0.053–0.164
Constipation	1,631	19	76.9	0.086	0.073–0.100	0.082	0.056–0.113
Abdominal pain	1,025	10	56.9	0.047	0.035–0.061	0.046	0.028–0.070
Myalgias	667	6	4.7	0.025	0.015–0.038	0.025	0.015–0.038
Nausea	870	10	42.4	0.023	0.014–0.034	0.023	0.011–0.038
Vomiting	972	11	40.1	0.023	0.014–0.033	0.022	0.012–0.036
Mucositis	773	9	56.2	0.02	0.011–0.031	0.02	0.006–0.041
Neuropathy	974	10	81.7	0.015	0.008–0.024	0.018	0.002–0.048
Infusion-site reaction	598	5	64	0.007	0.002–0.016	0.007	0.000–0.025

Abbreviation: CTCAE, Common Terminology Criteria for Adverse Events.